Tanvex BioPharma's Total Assets for the quarter that ended in Dec. 2024 was NT$2,735.14 Mil.
During the past 12 months, Tanvex BioPharma's average Total Assets Growth Rate was -1.00% per year.
During the past 3 years, the average Total Assets Growth Rate was -1.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 11.40% per year.
During the past 10 years, the average Total Assets Growth Rate was 16.70% per year.
During the past 12 years, Tanvex BioPharma's highest 3-Year average Total Assets Growth Rate was 63.20%. The lowest was -1.80%. And the median was 6.20%.
The historical data trend for Tanvex BioPharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Tanvex BioPharma's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma (TPE:6541) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Tanvex BioPharma's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Tanvex BioPharma Total Assets Related Terms
Thank you for viewing the detailed overview of Tanvex BioPharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TPE:6541 has been successfully added to your 